Pharmacodynamics in Paramedic Practice: Pharmacology Series

Abstract

Pharmacodynamics is the study of how drugs interact with the body to produce their effects, focusing on the mechanisms of drug action and their impact on physiological processes. It encompasses the exploration of four principal families of molecular targets—enzymes, receptors, ion channels, and transporters—and examines how drugs influence these targets to achieve therapeutic outcomes. Through an understanding of pharmacodynamics, paramedics can better engage with the evidence base underpinning commonly used medications, enhancing their ability to apply pharmacological principles to clinical practice effectively.

Key Words

Pharmacology; pharmacodynamics; paramedic drugs; mechanism of action

Introduction

Pharmacodynamics is the scientific study of the actions of drugs in the body, and how these actions generate physiological effects (Edwin, 2024). All physiological processes of the human body (healthy and pathological) are mediated by molecular pathways: the series of interactions between groups of molecules. To alter a patient's condition, a drug must target the specific molecules associated with it. The vast majority of drugs achieve this by binding tightly to their specific molecular targets, located either on the cell surface or within the cell (Bardal et. al, 2011), and is highly

dependent on the shape of the drug, such that it maximises the contact with its target. This concept is often compared to a jigsaw puzzle or a lock-and-key mechanism, where the drug binds only if it precisely fits the target. However, this analogy is not entirely accurate; drug-target binding exists on a spectrum, varying in strength and duration rather than being a simple ‘bind or not bind’ scenario. Drugs with a low affinity will bind very loosely and transiently to their target, whilst drugs with a high affinity bind incredibly tightly, some even irreversibly. Specific molecules involved in a given process can be identified, and their structure or shape mapped (Marion, 2013; Shi, 2014). Pharmacologists can then design drugs with complementary shapes to these molecular targets, enabling the drug to bind with appropriate affinity and modulate the molecule’s function as intended. For instance, designing drugs to treat asthma and Chronic Obstructive Pulmonary Disease (COPD) required understanding the pathways responsible for bronchoconstriction and tracheobronchial inflammation—specifically, the β2-adrenergic receptor and the glucocorticoid system. Following these discoveries, drugs such as Salbutamol and Fluticasone were developed (Barnes and Breckenridge, 2012).

Understanding where a drug binds—its molecular target—is therefore fundamental to determining its mechanism of action and the resulting impact on the patient. By identifying the specific molecular interactions, we can better comprehend how drugs influence physiological processes and contribute to therapeutic outcomes. Commonly, drug targets usually fall within one (or more) of four kinds of molecules: Enzymes, Receptors, Ion Channels and Transporters. Drugs exert either stimulatory (agonist) or inhibitory (antagonist) effects on molecular targets. Agonists activate or enhance target activity, while antagonists block or reduce it.

If a drug binds to the target's orthosteric site, it is competitive, competing with natural ligands based on affinity and concentration. Non-competitive drugs bind to an alternative site, known as the allosteric site, modifying target activity without competing for the same binding site.

Table 1 – Key definitions in pharmacodynamics	
Term	**Definition**
Pharmacodynamics	The study of how drugs affect the body and cause changes.
Enzyme	A protein that speeds up chemical reactions in the body.
Receptor	A protein that detects specific signals (like drugs) and triggers a response in the body.
Ion Channel	A protein in cell membranes that lets charged particles (ions) pass through, helping cells work.
Transporter	A protein that moves molecules or ions into or out of cells.
Agonist	A drug that activates a target (like a receptor) to produce an effect.
Antagonist	A drug that blocks a target (like a receptor) to reduce or stop its effect.
Affinity	How strongly a drug binds to its target.
Ligand	A molecule, like a drug, that binds to a specific target (such as a receptor).
Competitive	A drug that competes with natural substances for the same binding spot on a target.
Non-competitive	A drug that binds somewhere else on a target, changing how it works.

Enzymes

Enzymes are biological catalysts: molecular ‘machines’, usually comprised of protein, that greatly speed up specific chemical reactions. Mechanistically, enzymes are also reliant upon molecular binding to function. To catalyse a reaction, the substrates for

that reaction (ie: the ingredients) must become bound to the enzyme's active site (also known as an orthosteric site). After catalysis, the newly formed product is released from the enzyme into the cell or wider systemic circulation. Well over 3000 different biochemical processes are catalysed by enzymes (McDonald et al., 2009). Some are fundamental, like Adenosine Triphosphate (ATP) Synthase: found in abundance in each of the trillions of mitochondria throughout the human body (Hatton et al., 2023), turning Oxygen and Glucose into the 'energy molecule', ATP (Althaher and Alwahsh, 2023). Others are more specific, like Amylase, which helps process large, complex carbohydrates into readily usable glucose molecules (Peyrot des Gachons and Breslin, 2016). The staggering diversity of enzymes and the reactions they catalyse means that many enzymes are desirable targets for drugs.

For instance, various Non-Steroidal Anti-Inflammatory Drugs (NSAID), including Ibuprofen and Paracetamol (aka acetaminophen) target the enzyme Cyclooxygenase-2 (COX-2). COX-2 converts arachidonic acid (a lipid found in cell membranes), into a family of molecules called prostaglandins. These act as inflammatory mediators, causing pain, heat, vasodilation and increased vascular permeability (and therefore redness and swelling). By binding to the orthosteric site of COX-2, these NSAIDs prevent the substrate from binding, thereby reducing the amount of pro-inflammatory prostaglandins produced, and subsequently, the level of inflammation symptoms experienced. Another salient example is Angiotensin Converting Enzymes (ACE), responsible for conversion of Angiotensin I to Angiotensin II in the Renin-Angiotensin-Aldosterone System (RAAS) (Patel et al., 2017; Khurana and Goswami, 2022). Since RAAS is a natural mechanism for increasing blood pressure via vasoconstriction and reduced urine production, drugs that dampen RAAS by inhibiting ACE (eg: Ramipril,

Lisinopril, Enalapril) are a common family of anti-hypertension medications (Herman et al., 2024).

Receptors

Another common molecular target for drug binding are receptors: proteins that allow the cell to detect signals or stimuli, and subsequently transmit or transduce their own signal onwards. The majority of receptors respond to chemical signals: the binding of a specific molecule, called a ligand, onto the receptor at orthosteric site. In these receptors (also known as G-protein coupled receptors), ligand-binding causes the release of a small protein (called a G-protein) that carries the signal onwards by acting as a ligand with other receptors, causing release of more messenger molecules or interfering with the action of certain enzymes (Patel, 2021). Commonly, these receptors straddle the phospholipid bilayer, the membrane that forms the outer surface of all human cells. This allows cells with these receptors to detect incoming chemical signals from other cells via the systemic circulation, allowing communication between different biological systems.

As with enzymes, receptors are necessary for complex multicellular life, including every human bodily system; nervous system functioning relies on communication between neurons in the brain using neurotransmitters (eg: Serotonin, Dopamine, Acetylcholine etc.) as ligands to receptors embedded in specialised structures called synapses (Sheffler, 2023). White Blood cells of the immune system require various receptors to mount an effective immune response against invading pathogens (Shah et al., 2021; Duan et al., 2022). Again, the diversity of these process means that receptors can be leveraged as drug targets to treat various illnesses. Insulin and

Glucagon, important in the management of hyper- and hypoglycaemia patients, are ligands for receptors in the pancreas (Rahman, 2021; Jia, 2022); Morphine provides analgesia by binding to μ-Opioid receptors (Stein 2016).

In many cases, achieving a desired patient outcome, such as lowering blood pressure, can involve targeting multiple molecular pathways. While ACE inhibitors block the conversion of Angiotensin I to Angiotensin II, angiotensin receptor blockers (ARBs), such as Losartan, Valsartan, and Candesartan, directly inhibit the binding of Angiotensin II to its receptors, thereby preventing vasoconstriction and promoting vasodilation. Similarly, adrenergic receptors are another key target for hypertension management (NICE, 2023). Alpha blockers (e.g., Doxazosin, Prazosin) reduce blood pressure by inhibiting alpha-adrenergic receptors, leading to vasodilation, while beta blockers (e.g., Atenolol, Bisoprolol, Metoprolol) act on beta-adrenergic receptors to decrease heart rate and cardiac output (NICE, 2023).

Ion Channels

As with receptors, ion channels are large proteins imbedded in the phospholipid membrane of many cells, especially neurons (the cells of the nervous system). They serve as channels or tunnels for the passage of ions: atoms or molecules with a positive or negative electrical charge, into or out of a cell. Without them, the ions' electrical charge repels them from the membrane, making their passage across impossible. This movement of ions across cell membranes is vital for various biological processes, but is most important in the nervous system, where it serves as the basis for electrical nerve signals known as action potentials (Nerbonne and Kass, 2005; Varró, 2021). In the heart, ion fluxes underlie the electrical activity that generates the

rhythm observed on an ECG. Neurons (including those in the heart that generate a the cardiac rhythm) use Sodium and Potassium ions to generate these action potentials, which then travel along the neuron to stimulate a muscle to contract, or a gland to release a hormone, or another neuron to process information. Various drugs bind to ion channels to influence the rate or intensity at which these action potentials are generated. For instance, both Phenytoin's ability to prevent seizures and lidocaine's capacity as a local anaesthetic are granted by their binding and obstruction of Sodium Ion channels, preventing generation of action potentials. Similarly, amiodarone, a widely used antiarrhythmic drug, works by blocking potassium ion channels in cardiac cells. This action prolongs the repolarisation phase of the cardiac action potential and consequently stabilises the rhythm. In addition to enzymes and receptors, ion channels are important molecular targets in the treatment of hypertension. Calcium channel blockers, such as amlodipine, work by inhibiting calcium ion entry into vascular smooth muscle cells. This action reduces muscle contraction, promotes vasodilation, and ultimately lowers blood pressure.

Transporters

Finally, transporters serve as protein pumps that move important molecules into or out of cells. Whilst ions travel through ion channels along electrochemical gradients, larger molecules like antibiotics or neurotransmitters (Wen, 2016; Gether et al., 2006; Kristensen, et al., 2011) require transporters to facilitate their movement from one location to another. Additionally, in some cases transporters move ions against concentration gradients to create pools of them in specific areas. Once more, many transporters are disrupted by drugs to produce beneficial physiological changes.

155 Furosemide, used in the management of pulmonary oedema associated with
156 congestive heart failure, inhibits a family of transporters in the kidney, thereby
157 increasing urine production (diuresis)(Knox et al., 2024).

158

Table 2 – Examples of drugs and their molecular targets (information adapted from Knox et al., 2024)

Drug	**Example of Clinical Application(s)**	**Molecular Target**	**Mechanism**
Atropine	Bradycardia, Organophosphate Poisoning	RECEPTOR: Muscarinic Acetylcholine Receptors	Blocks muscarinic receptors, reducing parasympathetic activity to increase heart rate and reduce secretions.
Paracetamol	Pain	ENZYME: Cyclooxygenase (COX-2)	Inhibits COX-2, reducing prostaglandin production. Prostaglandins can contribute to pain
Phenytoin	Seizures	ION CHANNEL: Voltage-gated sodium channels	Blocks sodium channels, stopping hyperactive nerve signals.
Adrenaline	Anaphylaxis/Cardiac Arrest	RECEPTOR: Adrenergic Receptors (α & β)	Stimulates adrenergic receptors for increased heart rate and bronchodilation.
Ondansetron	Nausea/Vomiting	RECEPTOR: Serotonin (5-HT3) Receptors	Blocks serotonin receptors to prevent nausea signals.
Furosemide	Pulmonary oedema/Heart failure	TRANSPORTER: Na–K–Cl cotransporter	Inhibits ion reabsorption, increasing water excretion in the kidneys.
Midazolam	Sedation/Seizure Control	RECEPTOR: GABA-A Receptors	Enhances GABA activity for sedation and seizure control.
Morphine	Pain	RECEPTOR: μ-Opioid Receptors	Activates opioid receptors, reducing pain perception.
Naloxone	Opioid Overdose	RECEPTOR: μ-Opioid Receptors	Displaces opioids, reversing their effects.

Salbutamol	Asthma/COPD	RECEPTOR: β2-Adrenergic Receptors	Activates β2 receptors, causing bronchodilation.
Diazepam	Seizures	RECEPTOR: GABA-A Receptors	Enhances GABA signals, reducing anxiety and seizures.
Ibuprofen	Pain/Inflammation	ENZYME: Cyclooxygenase (COX-1 & COX-2)	Inhibits COX enzymes, reducing pain and inflammation.
Glucagon	Hypoglycaemia	RECEPTOR: Glucagon Receptors	Stimulates glycogen breakdown, raising blood sugar.
Lidocaine	Local Anaesthesia/Arrhythmias	ION CHANNEL: Voltage-gated sodium channels	Blocks sodium channels, stopping nerve signals.

Conclusion

Understanding pharmacodynamics is essential for comprehending how drugs interact with the body to produce therapeutic effects. By targeting enzymes, receptors, ion channels, and transporters, drugs can modulate key physiological processes to treat a wide range of conditions. It is likely the ever-increasing demands on paramedics and ever-changing nature of the roles will occur in tandem with the dramatic increases in new pharmacological treatments. Therefore, having a solid grasp of the foundational mechanisms by which drugs act upon the body's cells will equip paramedics to meet these advances, providing nuanced insight into the interactions between drugs and their targets that bring about desirable clinical outcomes.

CPD Questions

- Explain the four principal types of molecular targets for drugs (enzymes, receptors, ion channels, and transporters) and provide one example of a drug for each target type, including its mechanism of action.
- Identify a situation in your practice where understanding a drug's mechanism of action influenced your clinical decision-making or improved patient outcomes. What insights did you gain, and how might this knowledge shape your future practice?
- What strategies can you implement to deepen your understanding of pharmacodynamics and ensure you remain informed about emerging drug therapies relevant to paramedic practice?

Key Points

- Pharmacodynamics explains how drugs interact with the body at the molecular level, primarily through four key targets: enzymes, receptors, ion channels, and transporters.
- Most drugs work by altering existing biological pathways, either turning them on or off, or adjusting their activity up or down, to produce a desired physiological response. This targeted modulation aims to restore balance in the body and/or alleviate symptoms, enhancing patient outcomes.
- By understanding a drug's mechanisms of action, paramedics can better anticipate drug effects, adverse drug reactions, improve decision-making, and optimise patient outcomes in prehospital care.

References

Althaher AR, Alwahsh M. 2023. An overview of ATP synthase, inhibitors, and their toxicity. *Heliyon*. 9(11):e22459. doi:10.1016/j.heliyon.2023.e22459.

Bardal SK, Waechter JE, Martin DS. 2011. Basic principles and pharmacodynamics. In: Bardal SK, Waechter JE, Martin DS, editors. *Applied Pharmacology*. W.B. Saunders. p. 3-16. doi:10.1016/B978-1-4377-0310-8.00001-4.

Barnes PJ, Breckenridge A. 2012. David Jack (1924–2011) who revolutionised the treatment of asthma. *Thorax*. 67(3):266-267. doi:10.1136/thoraxjnl-2011-201522.

Duan T, Du Y, Xing C, Wang HY, Wang RF. 2022. Toll-like receptor signalling and its role in cell-mediated immunity. *Front Immunol*. 13:812774. doi:10.3389/fimmu.2022.812774.

Gether U, Andersen PH, Larsson OM, Schousboe A. 2006. Neurotransmitter transporters: molecular function of important drug targets. *Trends Pharmacol Sci*. 27(7):375-383. doi:10.1016/j.tips.2006.05.003.

Hatton IA, Galbraith ED, Merleau NSC, Miettinen TP, Smith BM, Shander JA. 2023. The human cell count and size distribution. *Proc Natl Acad Sci U S A*. 120(39):e2303077120. doi:10.1073/pnas.2303077120.

Herman LL, Padala SA, Ahmed I, Bashir K. 2024. Angiotensin-converting enzyme inhibitors (ACEI). In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431051/.

Jia Y, Liu Y, Feng L, Sun S, Sun G. 2022. Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes. *Front Endocrinol*. 13:928016. doi:10.3389/fendo.2022.928016.

Khurana V, Goswami B. 2022. Angiotensin converting enzyme (ACE). *Clin Chim Acta*. 524:113-122. doi:10.1016/j.cca.2021.10.029.

Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, Pon A, Cox J, Chin NEL, Strawbridge SA, Garcia-Patino M, Kruger R, Sivakumaran A, Sanford S, Doshi R, Khetarpal N, Fatokun O, Doucet D, Zubkowski A, Rayat DY, Jackson H, Harford K, Anjum A, Zakir M, Wang F, Tian S, Lee B, Liigand J, Peters H, Wang RQ, Nguyen T, So D, Sharp M, da Silva R, Gabriel C, Scantlebury J, Jasinski M, Ackerman D, Jewison T, Sajed T, Gautam V, Wishart DS. 2024. DrugBank 6.0: the DrugBank Knowledgebase for 2024. *Nucleic Acids Res*. 52(D1):D1265-D1275. doi:10.1093/nar/gkad976.

Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, Gether U. 2011. SLC6 neurotransmitter transporters: structure, function, and regulation. *Pharmacol Rev*. 63(3):585-640. doi:10.1124/pr.108.000869.

Marion D. 2013. An introduction to biological NMR spectroscopy. *Mol Cell Proteomics*. 12(11):3006-3025. doi:10.1074/mcp.O113.030239.

McDonald AG, Boyce S, Tipton KF. 2009. ExplorEnz: the primary source of the IUBMB enzyme list. *Nucleic Acids Res*. 37:D593-D597. doi:10.1093/nar/gkn582.

National Institute for Health and Care Excellence (NICE) (2023) Hypertension in adults: diagnosis and management. National Institute for Health and Care Excellence guideline NG136. August 2019 (updated November 2023).

https://www.nice.org.uk/guidance/ng136

Nerbonne JM, Kass RS. 2005. Molecular physiology of cardiac repolarization. *Physiol Rev*. 85(4):1205-1253. doi:10.1152/physrev.00002.2005.

Patel D. 2021. Prescribing for paramedics: Pharmacodynamics. *J Paramed Pract*. 13(3). doi:10.12968/jpar.2021.13.3.96.

Patel S, Rauf A, Khan H, Abu-Izneid T. 2017. Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. *Biomed Pharmacother*. 94:317-325. doi:10.1016/j.biopha.2017.07.091.

Peyrot des Gachons C, Breslin PA. 2016. Salivary amylase: digestion and metabolic syndrome. *Curr Diab Rep*. 16(10):102. doi:10.1007/s11892-016-0794-7.

Qadir, M. I., Bukhat, S., Rasul, S., Manzoor, H., Manzoor, M. 2020. RNA therapeutics: Identification of novel targets leading to drug discovery. *Journal of cellular biochemistry*, *121*(2), 898–929. https://doi.org/10.1002/jcb.29364

Rakel RE. 2024. therapeutics. *Encyclopaedia Britannica*. Available from: https://www.britannica.com/science/therapeutics.

Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, Hannan MA, Uddin MJ, Pang MG. 2021. Role of Insulin in Health and Disease: An Update. *Int J Mol Sci*. 22(12):6403. doi:10.3390/ijms22126403.

Shah K, Al-Haidari A, Sun J, Kazi JU. 2021. T cell receptor (TCR) signalling in health and disease. *Signal Transduct Target Ther*. 6(1):412. doi:10.1038/s41392-021-00823-w.

Sheffler ZM, Reddy V, Pillarisetty LS. 2023. Physiology, Neurotransmitters. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539894/.

Shi Y. 2014. A glimpse of structural biology through X-ray crystallography. *Cell*. 159(5):995-1014. doi:10.1016/j.cell.2014.11.014.

264 Stein C. 2016. Opioid Receptors. *Annu Rev Med*. 67:433-451. doi:10.1146/annurev-
265 med-062613-093100.

266 Wen JH, Wei XH, Zhou J, Peng HW, Lu YN, Li YH, Cao DW, Zhou Y, Cao L. 2016.
267 The role of drug transporters in the pharmacokinetics of antibiotics. *Curr Drug Metab*.
268 17(8):762-773. doi:10.2174/1389200217666160629114449.